Literature DB >> 2311331

Famotidine. Pharmacokinetic properties and suppression of acid secretion in paediatric patients following cardiac surgery.

G Kraus1, D R Krishna, D Chmelarsch, M Schmid, U Klotz.   

Abstract

The pharmacokinetic and pharmacodynamic properties of the H2-receptor antagonist famotidine have been well described in adult subjects. However, similar data for children are not available. Therefore, this study looked at the disposition of the drug (given to prevent aspiration following cardiac surgery) in 10 paediatric patients with normal kidney function (age range 2 to 7 years, bodyweight 14 to 25 kg) after a single intravenous dose of famotidine 0.3 mg/kg. Plasma concentrations of the drug and gastric pH values were both monitored for 20 hours by high performance liquid chromatography and aspiration of gastric juice, respectively. Plasma famotidine concentrations declined with an elimination half-life of 3.3 +/- 1.8 h (mean +/- SD) and the drug was effective in elevating the gastric pH above 3.5 for about 9 hours in 6 patients. The variable volume of distribution and total plasma clearance of famotidine averaged 1.4 +/- 1.0 L/kg and 0.3 +/- 0.17 L/h/kg, respectively. In 4 patients unchanged famotidine could also be measured in a 12-hour urine fraction. The amount excreted (21 to 79%) correlated with clearance (r = 0.97). All these data are comparable to those obtained in healthy adults, indicating that paediatric patients receiving intensive medical treatment after cardiac surgery can handle famotidine in a way very similar to healthy adult subjects. A dosage of 0.3 mg/kg every 8 hours appears to be advisable.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2311331     DOI: 10.2165/00003088-199018010-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  16 in total

1.  Pharmacokinetics and dynamics of famotidine in patients with renal failure.

Authors:  U Gladziwa; U Klotz; D R Krishna; H Schmitt; W M Glöckner; H Mann
Journal:  Br J Clin Pharmacol       Date:  1988-09       Impact factor: 4.335

2.  Plasma famotidine concentration versus intragastric pH in patients with upper gastrointestinal bleeding and in healthy subjects.

Authors:  H Echizen; R Shoda; N Umeda; T Ishizaki
Journal:  Clin Pharmacol Ther       Date:  1988-12       Impact factor: 6.875

3.  Pharmacokinetics of ranitidine in critically ill infants.

Authors:  D B Wiest; W O'Neal; J R Reigart; R C Brundage; P C Gillette; R L Yost
Journal:  Dev Pharmacol Ther       Date:  1989

Review 4.  Newer H2-receptor antagonists. Clinical pharmacokinetics and drug interaction potential.

Authors:  D R Krishna; U Klotz
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

5.  Effects of antacids and food on absorption of famotidine.

Authors:  J H Lin; A N Chremos; S M Kanovsky; S Schwartz; K C Yeh; J Kann
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

6.  Inhibition of gastric secretion by a new H2-antagonist, YM-11170 in healthy subjects.

Authors:  M Miwa; N Tani; T Miwa
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1984-04

7.  Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function.

Authors:  T Takabatake; H Ohta; M Maekawa; Y Yamamoto; Y Ishida; H Hara; S Nakamura; Y Ushiogi; M Kawabata; N Hashimoto
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Pharmacokinetics of famotidine in man.

Authors:  H Kroemer; U Klotz
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1987-08

Review 9.  The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients.

Authors:  A Bodenham; M P Shelly; G R Park
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

Review 10.  Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.

Authors:  D M Campoli-Richards; S P Clissold
Journal:  Drugs       Date:  1986-09       Impact factor: 9.546

View more
  3 in total

1.  Pharmacokinetics of famotidine in infants.

Authors:  Larissa A Wenning; M Gail Murphy; Laura P James; Jeffrey L Blumer; James D Marshall; John Baier; Ann O Scheimann; Deborah L Panebianco; Ling Zhong; Roy Eisenhandler; Kuang C Yeh; Gregory L Kearns
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Pharmacokinetics and pharmacodynamics of famotidine in paediatric patients.

Authors:  L P James; G L Kearns
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of famotidine.

Authors:  H Echizen; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.